<p><em>In September 2011, the Research Institute of Uronephrology and Human Reproductive Health began to use an apparatus for the early diagnosis of prostate cancer. One hundred and fifty-six studies have been conducted by now. In the examinees, the level of prostate-specific antigen was estimated to be in the range of 1.09 to 209 ng/ml. The results of the studies confirm European data on the sensitivity and specificity of this procedure.</em></p
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.